Evidence map›Paper›PMID 32365886›Full record

ReviewMolecules (Basel, Switzerland)2020

Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment.

Manuela Curcio, Annafranca Farfalla, Federica Saletta, Emanuele Valli, Elvira Pantuso, Fiore Pasquale Nicoletta, Francesca Iemma, Orazio Vittorio, Giuseppe Cirillo

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Manuela CurcioDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy.
Annafranca FarfallaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy.
Federica SalettaLowy Cancer Research Centre, Children's Cancer Institute, UNSW Sydney, NSW 2031, Australia.
Emanuele ValliLowy Cancer Research Centre, Children's Cancer Institute, UNSW Sydney, NSW 2031, Australia.
Elvira PantusoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy.
Fiore Pasquale NicolettaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy.ORCID 0000-0001-5961-1963
Francesca IemmaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy.
Orazio VittorioLowy Cancer Research Centre, Children's Cancer Institute, UNSW Sydney, NSW 2031, Australia.
Giuseppe CirilloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy.ORCID 0000-0002-9592-1333

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbon nanostructures (CN) are emerging valuable materials for the assembly of highly engineered multifunctional nanovehicles for cancer therapy, in particular for counteracting the insurgence of multi-drug resistance (MDR). In this regard, carbon nanotubes (CNT), graphene oxide (GO), and fullerenes (F) have been proposed as promising materials due to their superior physical, chemical, and biological features. The possibility to easily modify their surface, conferring tailored properties, allows different CN derivatives to be synthesized. Although many studies have explored this topic, a comprehensive review evaluating the beneficial use of functionalized CNT vs G or F is still missing. Within this paper, the most relevant examples of CN-based nanosystems proposed for MDR reversal are reviewed, taking into consideration the functionalization routes, as well as the biological mechanisms involved and the possible toxicity concerns. The main aim is to understand which functional CN represents the most promising strategy to be further investigated for overcoming MDR in cancer.

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1CarbonDrug CarriersDrug Delivery SystemsDrug Resistance, MultipleHumansNanostructuresNeoplasmsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1CarbonDrug Carrierscancer therapycarbon nanohybridscarbon nanostructuresmulti-drug resistance

Identifiers

PMID32365886
PMCPMC7249046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.